<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
September 19, 1995
SYNTHETECH, INC.
(Exact name of registrant as specified in its charter)
Oregon 0-12992 84-0845771
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation or organization) File Number) Identification No.)
1290 Industrial Way, Albany, Oregon 97321
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code:
(503) 967-6575
<PAGE>
Item 5 Other Events
The Press Release attached as Exhibit A hereto is incorporated by reference
herein.
<PAGE>
SIGNATURES
In accordance with the requirements of the Exchange Act, the registrant caused
this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
SYNTHETECH, INC.
(Registrant)
Date: September 19, 1995 /s/ M. Sreenivasan
M. Sreenivasan
President & C.E.O.
Date: September 19, 1995 /s/ Charles B. Williams
Charles B. Williams
Vice President, Finance
and Administration,
Chief Accounting Officer
<PAGE>
EXHIBIT A
For release Monday, September 18, 1995, 1:05 PM (Pacific Time)
SYNTHETECH ANNOUNCES PLANS TO CONSTRUCT NEW PLANT
Albany, OR, September 18, 1995 -- Synthetech, Inc. (NASDAQ - NZYM) announced
today plans to build a multi-million dollar manufacturing plant to increase
its capacity to produce pharmaceutical intermediates. The new plant will be
built on a site adjacent to its existing facilities in Albany, Oregon. The
Company expects to complete construction by the end of 1996.
M. 'Sreeni' Sreenivasan, President & CEO, noted, "As our business has
evolved, the Company is approaching manufacturing capacity constraints in its
existing facility. The new plant will allow us to continue our track record
of responsive service to our pharmaceutical customers worldwide. With this
expansion, we believe that the Company will be strategically positioned to
respond rapidly to new opportunities as they develop." While this is a
significant and exciting development, he cautioned that the Company continues
to expect fluctuations in quarterly revenues due to the business and
regulatory dynamics inherent in pharmaceutical development.
Synthetech's Peptide Building Blocks and specialty amino acids are used by
pharmaceutical companies to make a wide range of drugs under development as
potential therapies for AIDS, cancer, cardiovascular and other diseases.
MORE INFORMATION:
M "Sreeni" Sreenivasan, President & CEO (503)967-6575
Charlie Williams, CFO (503)967-6575
